To effectively address critical questions related to the adoption and deployment of in silico methods for specific topics, the Avicenna Alliance has established dedicated Task Forces, composed of experts from various fields, ensuring a multidisciplinary approach to solving complex issues.
These groups collaborate to achieve concrete progress for matters as diverse as In silico AI, Patient involvement, Horizon Europe Projects, Pharmaceutical strategy, In silico oncology, Notified Bodies and Standard Organizations, etc.
By leveraging diverse expertise and fostering strong industry-academia relationships – each Task Force is led by 2 co-chairs one from academia and one from industry - the Task Forces aim to pave the way for widespread implementation and acceptance of in silico practices, ultimately benefiting patients and advancing scientific progress.
NEWS

In Silico Medicine: A New Scientific Discipline Emerges in Greece
On December 21, 2024, Research Professor Georgios S. Stamatakos, a great pioneer of in silico oncology, delivered a lecture in Sparta, Greece, exploring the emergence, evolution, and clinical potential of in silico medicine.

Introducing the plain language in silico medicine glossary
As in silico medicine continues to advance, new concepts and terms emerge rapidly—often before widespread consensus is established. To make this transformative field more accessible to all the stakeholders including the patients, we are pleased to present the “Plain language in silico medicine glossary”, now published on Zenodo.

Happy New Year, 2025, the Millennium Year
Dear Avicenna Alliance members, As we welcome the new year, we hope you had a joyful holiday season filled with moments of relaxation and happiness with your loved ones.